Page 13 - Flipbook

Single-Agent IO Activity in Front-line mRCC: Is PD-L1 Inhibition Inferior?

IMmotion 150 1 JAVELIN 1b 2 KEYNOTE-427 3 HCRN 4
(Atezolizumab) (Avelumab) (Pembro) 2 (Nivolumab)

N=103 N=62 N=110 N=123

Anti PD-L1 Anti PD-1

IMDC F/I/P 25% favorable 39% favorable 38% favorable 28% favorable

75% int/poor 61% int/poor 62% int/poor 72% int/poor

mPFS, mos. 6.1 8.3 7.1 8.3

2-year Landmark 35% 15% 22% 25%

PFS

ORR 25% 16% 36% 34%

CR 11% 2% 4% 7%

Primary PD NR 18% 30% 30%

Med f/u, mos 20.7 26.2 35.9 26.9

1 McDermott et al. Nature Med 2018. 2. McDermott et al. JCO 2021 3. Atkins et al. JCO 2022 4. Vaishampayan et al. JITC 2019